Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>CHL1</i> could co-localize with adhesion molecule Integrin-β1, the expression of <i>CHL1</i> was positively correlated with Integrin-β1 and another known tumor suppressor gene (TSG) Merlin.
|
31523184 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD29(+) tumors were more resistant to radiotherapy and cisplatin therapy than CD29(-) tumors.
|
25805567 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Integrin β1 (ITGB1) has been recognized to play a major role in tumor growth, invasion and metastasis.
|
25894721 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
|
27289231 |
2016 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancer.
|
29402961 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD44v6 and integrin-β1 gene expression were not associated with the sex, age, and tumor position in PC (P>0.05).
|
22695923 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Complexes formed by TG2, fibronectin (FN), and integrin β1 were enriched in ovarian CSC and detectable in tumors.
|
29510995 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistently, sh-RNA mediated knocking down of ITGB1 evidently reduced tumor growth and peritoneal dissemination in in vivo Nod-scid SKOV3 orthotopic xenograft mice.
|
24931361 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
During the analysis of data, key molecules (brevican, cadherin-12, fibronectin and integrin-β1) correlating the most with tumor grade were selected.
|
28161812 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ectopic overexpression of uPAR in human MDA-MB-468 breast cancer cells promoted the emergence of a CD24(-)/CD44(+) phenotype, characteristic of CSCs, while increasing the cell surface abundance of integrin subunits β1/CD29 and α6/CD49f that represent putative mammary gland stem cell biomarkers. uPAR overexpression increased mammosphere formation in vitro and tumor formation in an immunocompromized severe combined immunodeficient (SCID) mouse model of orthotopic breast cancer.
|
20940399 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fibronectin (FN), a ligand of integrin β1, was used to verify the correlation between alterations in the integrin β1/FAK pathway and changes in tumor cell aggressiveness upon PFN1 perturbation.
|
25741138 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, silencing miR-29c markedly increased Taxol-resistant NPC tumor growth in a nude mouse xenograft model while knockdown of ITGB1 reversed this result.
|
30779921 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we find that in melanoma, integrin β1-mediated TGF-β activation may also produce tumor suppression via an altered host response.
|
28448494 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we tested therapeutic potential of OS2966-mediated integrin β1 blockade to enhance the efficacy of oncolytic herpes simplex virus-1 (oHSV) through evaluation of virus replication, tumor cell killing efficiency, effect on the antiviral signaling pathway, co-culture assays of oHSV-infected cells with macrophages, and <i>in vivo</i> bioluminescence imaging on mammary fat pad triple-negative breast cancer xenograft and subcutaneous and intracranial glioma xenografts.
|
30926634 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry, RT-PCR and western blot analyses were used to detect HIF-1α and ITGβ1 expression in the tumor nodules of the greater omentum.
|
27004522 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, our results provide the first evidence that ITGB1 is a direct target of miR-493-5p suggesting that ITGB1 and miR-493-5p may have potential prognostic value and may be useful as tumor biomarkers for the diagnosis of NSCLC patients.
|
28537888 |
2017 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
KRas G12V primary tumors showed Akt activation, and β5 integrin, vascular endothelial growth factor A (VEGFA), and Serpine-1 overexpression, whereas KRas G13D tumors showed integrin β1 and angiopoietin 2 (Angpt2) overexpression.
|
25359494 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, ITGB1 promoted the proliferation of cells in a xenograft tumor mouse model.
|
24807392 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, all epithelial subpopulations (CD29(hi)CD24(+), CD29(lo)CD24(+), CD29(hi)CD24(+)Thy1(+)) in tumors from high-fat-diet-exposed offspring were refractory to doxorubicin.
|
27402613 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting integrin beta(1) functionality reduced Ras-driven tumorigenesis in vivo and validated the network modeling strategy for predicting genes essential to neoplasia.
|
19829083 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was to investigate the use of PODXL, BCL7B, ARHGEF4, and the integrin family member ITGB1 as useful markers for the prognosis of postoperative pancreatic cancer patients in comparison with tumor size and the tumor node metastasis (TNM) staging system.
|
31166991 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of integrin β1 in the tumor specimens of laryngeal cancer patients was assessed by immunohistochemical assays.
|
29930482 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results of the present study indicated that ITGB1 was upregulated in HO‑8910 and HO‑8910PM ovarian cancer cell lines, and knockdown of ITGB1 using short hairpin RNA markedly increased tumor cell apoptosis, decreased tumor cell adhesion and migration, and reduced tumor cell invasion by suppressing matrix metalloproteinase (MMP)‑2 and MMP‑9 expression.
|
26497667 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The treatment efficacy, levels of sPD-L1 tumor marker CEA (carcino-embryonic antigen), and T-lymphocyte subsets (CD4+, CD3+, CD8+, CD29+) were compared between the two groups.
|
31128008 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data highlight that suppression of the Kindlin-2-integrin β1-AKT regulatory axis is an alternative mechanism underlying the tumor suppressor function of miR-200b in ESCC.
|
26334393 |
2015 |